Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity

Lung Cancer

Volumn 47, Issue 1, 2005, Pages 129-138

  Chiu, Chao Hua ^a,b   Tsai, Chun Ming ^a,b   Chen, Yuh Min ^a,b   Chiang, Shu Chen ^a   Liou, Jia Ling ^a   Perng, Reury Perng ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Brain metastasis; Gefitinib; Non small cell lung cancer; Skin toxicity

Indexed keywords

GEFITINIB;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN METASTASIS; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; PRIORITY JOURNAL; SINGLE DRUG DOSE; SKIN TOXICITY;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; QUINAZOLINES; TREATMENT OUTCOME;

EID: 10444237217     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2004.05.014     Document Type: Article

References (36)

1. Jemal A., Murray T., Samuels A., Ghafoor A., Ward E., Thun M.J. Cancer statistics. CA Cancer J. Clin. 53:2003;5-26
2. Newman S.J., Hansen H.H. Frequency, diagnosis, and treatment of brain metastases in 247 consecutive patients with bronchogenic carcinoma. Cancer. 33:1974;492-496
3. Cox J.D., Yesner R.A. Adenocarcinoma of the lung: recent results from the Veterans Administration Lung Group. Am. Rev. Respir. Dis. 120:1979;1025-1029
4. Ryan G.F., Ball D.L., Smith J.G. Treatment of brain metastases from primary lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 31:1995;273-278
5. Rosner D., Nemoto T., Lane W.W. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer. 58:1986;832-839
6. Rustin G.J., Newlands E.S., Bagshawe K.D., Begent R.H., Crawford S.M. Successful management of metastatic and primary germ cell tumors in the brain. Cancer. 57:1986;2108-2113
7. Kristensen C.A., Kristjansen P.E.G., Hansen H.H. Systemic chemotherapy of brain metastases from small-cell lung cancer: a review. J. Clin. Oncol. 10:1992;1498-1502
8. Minotti V., Crino L., Meacci M.L., et al. Chemotherapy with cisplatin and teniposide for cerebral metastases in non-small cell lung cancer. Lung Cancer. 20:1998;93-98
9. Bernardo G., Cuzzoni Q., Strada M.R., et al. First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non-small-cell lung cancer: a phase II study. Cancer Invest. 20:2002;293-302
10. Cortes J., Rodriguez J., Aramendia J.M., et al. Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer. Oncology. 64:2003;28-35
11. Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 21:2003;2237-2246
12. Kris M.G., Natale R.B., Herbst R.S., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 290:2003;2149-2158
13. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899-909.
14. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst. 92:2000;205-216
15. Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 47:1981;207-214
16. Hollen P.J., Gralla R.J., Kris M.G., Potanovich L.M. Quality of life assessment in individuals with lung cancer: testing the lung cancer symptom scale (LCSS). Eur. J. Cancer. 29A:1993;S51-S58
17. Ranson M., Hammond L.A., Ferry D., et al. ZD1839('Iressa'), a selective oral EGFR-TKI (epidermal growth factor receptor tyrosine kinase inhibitor) is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J. Clin. Oncol. 20:2002;2240-2250
18. Heimberger A.B., Learn C.A., Archer G.E., et al. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (Iressa). Clin. Cancer Res. 8:2002;3496-3502
19. Rich J.N., Reardon D.A., Peery T., et al. Phase II trial of gefitinib in recurrent glioblastoma. J. Clin. Oncol. 22:2004;133-142
20. Iacono L.C., Geyer J.R., Kun L.E., et al. Pharmacokinetics of gefitinib in children with brain tumors. Proc. Am. Soc. Clin. Oncol. 22:2003;132a
21. Villano J.L., Mauer A.M., Vokes E.E. A case study documenting the anticancer activity of ZD1839 (Iressa) in the brain. Ann. Oncol. 14:2003;656-658
22. Cappuzzo F., Ardizzoni A., Soto-Parra H., et al. Epidermal growth factor receptor targeted therapy by ZD1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC). Lung Cancer. 41:2003;227-231
23. Cappuzzo F., Calandri C., Bartolini S., Crino L. ZD1839 in patients with brain metastases from non-small cell lung cancer (NSCLC): report of four cases. Br J Cancer. 89:2003;246-247
24. Postmus P.E., Smit E.F. Chemotherapy for brain metastases of lung cancer: a review. Ann Oncol. 10:1999;753-759
25. Katakami N., Okazaki M., Kinose D., et al. A retrospective analysis of the outcome of patients (pts) in advanced recurrent adenocarcinoma of the lung who have received gefitinib after treatment of platinum-base regimen. Proc. Am. Soc. Clin. Oncol. 22:2003;666a
26. Wong N.S., Lim S.T., Lim W.T., Leong S.S., Tan E.H. ZD1839 is more effective in patients with non-small cell lung cancer (NSCLC) who were lifetime non-tobacco users. Proc. Am. Soc. Clin. Oncol. 22:2003;694a
27. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Sci. Expr. [published online 29 April 2004].
28. Inoue A., Saijo Y., Maemondo M., et al. Severe acute interstitial pneumonia and gefitinib. Lancet. 361:2003;137-139
29. Tamura K., Yamamoto N., Takeda K., et al. Am epidemiological survey for interstitial lung disease induced by gefitinib in patients with advanced non-small cell lung cancer. West Japan Thoracic Oncology Group (WJTOG). Eur. J. Cancer Suppl. 1(5):2003;S21
30. Cohen E.E.W., Rosen F., Stadler W.M., et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. 21:2003;1980-1987
31. Janne P.A., Gurubhagavatula S., Lucca J., et al. Clinical benefits in patients with advanced non-small-cell lung cancer treated with gefitinib ("Iressa", ZD1839) in the compassionate use program. Lung Cancer. 41(Suppl 2):2003;S71
32. Perez-Soler R., Chachoua A., Huberman M., et al. Final results from a phase II study of erlotinib (Tarceva) monotherapy in patients with advanced non-small cell lung cancer following failure of platinum-based chemotherapy. Lung Cancer. 41(Suppl 2):2003;S246-S247
33. Clark G.M., Perez-Soler R., Siu L., Gordon A., Santabaabara P. Rash severity is predictive of increased survival with erlotinib HCl. Proc. Am. Soc. Clin. Oncol. 22:2003;196a
34. Saltz L., Kies M., Abbruzzese L., et al. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc. Am. Soc. Clin. Oncol. 22:2003;204a
35. Lynch T., Ranson M., Herbst R., et al. Skin toxicity is not a clinical prognostic marker for tumor response to gefitinib (Iressa, ZD1839) in pre-treated patients with advanced non-small cell lung cancer. Clin. Cancer Res. 9(Suppl 16):2003;70
36. Reynolds N.J., Talwar H.S., Baldassare J.J., et al. Differential induction of phosphatidylcholine hydrolysis, diacylglycerol formation and protein kinase C activation by epidermal growth factor and transforming growth factor-alpha in normal human skin fibroblasts and keratinocytes. Biochem. J. 294:1993;535-544